Read by QxMD icon Read


Kazuo Kobayashi, Kazuyoshi Kawakami, Takashi Yokokawa, Takeshi Aoyama, Kenichi Suzuki, Takeru Wakatsuki, Mitsukuni Suenaga, Hitoshi Sato, Erika Sugiyama, Kensei Yamaguchi, Toshihiro Hama
PURPOSE: Hand-foot skin reaction (HFSR) can deteriorate quality of life in patients receiving regorafenib. Cutaneous toxicity is a main adverse effect of multikinase inhibitors and has also been associated with clinical outcome. This study assessed the association between the antitumor efficacy of regorafenib and HFSR in patients with metastatic colorectal cancer (mCRC). METHODS: Patients who received regorafenib at 160 mg/day during the first 3 weeks of each 4-week cycle were divided into subgroups based on whether they developed HFSR between May 2013 and October 2015...
February 14, 2019: Oncology
Natalja Eigeliene, Jatta Saarenheimo, Antti Jekunen
Cancer therapy decisions are often made according to the histopathological-molecular profile of tumor tissue obtained from surgery or biopsy. It has been shown that tumor profiles change with time and treatment, and that tumor tissue is heterogeneous. Thus, other approaches that are easily accessible and less invasive than surgery or biopsy to monitor responses to treatment and predict relapses are urgently needed. In the last few years, the term "liquid biopsies" has been introduced to represent multifunctional circulating biomarkers in the peripheral blood and other physiological fluids of patients with cancer...
January 17, 2019: Oncology
Hideki Iwamoto, Mika Nomiyama, Takashi Niizeki, Shigeo Shimose, Tomotake Shirono, Masahito Nakano, Manabu Satani, Syusuke Okamura, Yu Noda, Naoki Kamachi, Miwa Sakai, Hiroyuki Suzuki, Ryoko Kuromatsu, Etsuyo Ogo, Toshi Abe, Masatoshi Tanaka, Hironori Koga, Takuji Torimura
AIM: Prognosis of hepatocellular carcinoma (HCC) with macrovascular invasion (MVI) is extremely poor. However, proper therapeutic strategies have not been established yet. The purpose of this study is to identify the effects of external beam radiation therapy (EBRT) for MVI of HCC. METHODS: We have analyzed and evaluated 80 consecutive patients with HCC with MVI who underwent EBRT, and factors associated with enhanced survival in EBRT were evaluated by univariate and multivariate analysis...
January 16, 2019: Oncology
Li Rebekah Feng, Timothy Fuss, Kristin Dickinson, Alexander Ross, Leorey N Saligan
PURPOSE: Cancer-related fatigue is one of the most debilitating side effects of cancer and cancer therapy. We aimed to investigate co-occurring symptoms associated with persistent fatigue in men receiving external beam radiation therapy (EBRT) for nonmetastatic prostate cancer. METHODS: A sample of 47 men with prostate cancer scheduled to receive radiotherapy (RT) were followed at baseline and 1 year after RT. Clinical and demographic data were obtained from chart review...
January 9, 2019: Oncology
Kuo-Hsing Chen, Liang-In Lin, Li-Hui Tseng, Yu-Lin Lin, Jau-Yu Liau, Jia-Huei Tsai, Jin-Tung Liang, Been-Ren Lin, Ann-Lii Cheng, Kun-Huei Yeh
OBJECTIVE: We aimed to study the prognostic role of CpG island methylator phenotype (CIMP) in patients with different stages of colorectal cancer (CRC). MATERIAL AND METHODS: We analyzed CIMP in stage I-IV CRC specimens from patients who were diagnosed between 2005 and 2013. CIMP status was determined using a 5-gene MethyLight-based assay. The clinicopathologic characteristics were reviewed and the overall survival (OS) was compared between patients with CIMP-high CRC and those with CIMP-low/negative CRC...
December 12, 2018: Oncology
Paul Martin Putora
No abstract text is available yet for this article.
December 12, 2018: Oncology
Peeter Karihtala, Katja Porvari, Ylermi Soini, Matti Eskelinen, Petri Juvonen, Kirsi-Maria Haapasaari
OBJECTIVES: Protein levels of the transcription factor nuclear factor erythroid-derived 2-like 2 (Nrf2) and its inhibitor Kelch-like ECH-associated protein 1 (Keap1) have been proposed as prognostic factors in pancreatic ductal adenocarcinomas (PDACs). These cellular redox-state-regulating enzymes are targeted by several microRNAs, including miR-93 and miR-200a. METHODS: We assessed mRNA levels of Nrf2 and Keap1 and tissue expression of miR-93 and miR-200a in 51 patients with surgically treated PDAC...
December 11, 2018: Oncology
Frank A Giordano, Grit Welzel, Victor Siefert, Lennart Jahnke, Thomas Ganslandt, Frederik Wenz, Anca-Ligia Grosu, Felix Heinemann, Nils H Nicolay
There is accumulating evidence from randomized trials suggesting that digital patient-centered care allows a more reliable detection of tumour-related symptoms and adverse events - with a direct impact on overall survival. Consequently, a variety of unsynchronized approaches were kicked off to (electronically) measure patient-reported outcomes (PROs). Despite increasing evidence that PRO data are highly relevant for patient care, the data generated in these initial projects lack standardized processing pathways in order to impact clinical routine; therefore, potential future routine PRO assessments require adequate analysis, storage and processing to allow a robust, reproducible and reliable incorporation into routine clinical decision-making...
December 5, 2018: Oncology
Oscar Arrieta, Andrés F Cardona, Guillermo Bramuglia, Graciela Cruz-Rico, Luis Corrales, Claudio Martín, Victoria Imaz-Olguín, Omar Castillo, Mauricio Cuello, Érica Rojas-Bilbao, Gabriel Casas, Cristina Fernández, Osvaldo Arén Frontera, Valeria Denninghoff, Gonzalo Recondo, Alejandro Avilés-Salas, Luis-Alberto Mas-Lopez, George Oblitas, Leonardo Rojas, Antonio Piottante, Ernesto Jiménez-García, Sergio Sánchez-Sosa, Julia Sáenz-Frias, Hernán Lupera, Laura Alejandra Ramírez-Tirado, Carlos Vargas, Hernán Carranza, Horacio Astudillo, Laura Beatriz Wills, Ernestina Pichelbaur, Luis E Raez
OBJECTIVE: Latin American countries are heterogeneous in terms of lung cancer incidence and exposure to potential carcinogens. We evaluated the frequency and clinical characteristics of ALK rearrangements (ALKr) in Latin America. METHODS: A total of 5,130 lung cancer patients from 10 Latin American countries were screened for inclusion. ALKr detection was performed by fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), and real-time reverse transcriptase-polymerase chain reaction (RT-PCR) to assess method variability...
November 26, 2018: Oncology
Huan-Hsin Tseng, Lise Wei, Sunan Cui, Yi Luo, Randall K Ten Haken, Issam El Naqa
In the era of personalized and precision medicine, informatics technologies utilizing machine learning (ML) and quantitative imaging are witnessing a rapidly increasing role in medicine in general and in oncology in particular. This expanding role ranges from computer-aided diagnosis to decision support of treatments with the potential to transform the current landscape of cancer management. In this review, we aim to provide an overview of ML methodologies and imaging informatics techniques and their recent application in modern oncology...
November 23, 2018: Oncology
Takuya Ishikawa, Hiroki Kawashima, Eizaburo Ohno, Hiroshi Matsubara, Yoji Sasaki, Koichi Achiwa, Akira Kanamori, Hajime Sumi, Takanori Hirai, Koji Nonogaki, Tomoyuki Tsuzuki, Masanori Kuroiwa, Masashi Hattori, Shinya Maruta, Takeshi Hiramatsu, Masahiko Ando, Senju Hashimoto, Yoshiki Hirooka
OBJECTIVE: To evaluate the efficacy and safety of alternate-day administration of S-1 as second-line chemotherapy for unresectable pancreatic cancer in a multicenter, randomized, phase II study. METHODS: Patients with histologically proven, unresectable pancreatic cancer treated with chemotherapy not including S-1 as first-line therapy were randomly assigned to receive either daily or alternate-day treatment with S-1. The primary end point was overall survival (OS), and the secondary end points were progression-free survival (PFS), time to treatment failure (TTF), response rate, and adverse events...
2019: Oncology
Sook-Hee Hong, Ho Jung An, Kihyun Kim, Seung Sei Lee, Yun-Gyoo Lee, Young-Jin Yuh, I Cheon Park, Yee Soo Chae, Tae-Won Jang, Jin-Hyoung Kang
OBJECTIVES: Anti-angiogenic agents are reported to exert clinical activity on epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancers. We evaluated the clinical outcomes of nintedanib and docetaxel in refractory NSCLC according to EGFR mutation status during the Korean nintedanib named patient program. METHODS: Docetaxel was administered either 75 or 37.5 mg/m2 on D1, D8 q every 3 weeks for 4-6 cycles plus nintedanib 200 mg orally twice daily until disease progression or unacceptable toxicity...
2019: Oncology
Aslı Suner, Brian I Carr, Hikmet Akkiz, Gökhan Karakülah, Oguz Üsküdar, Kendal Yalçın, Sedef Kuran, Yaman Tokat, Sezai Yilmaz, Ayşegül Özakyol, Salih Tokmak, Tuğsan Ballı, Mehmet Yücesoy, Halil İbrahim Bahçeci, Abdulalh Ülkü, Tolga Akçam, Kamil Yalçın Polat, Nazım Ekinci, Halis Şimşek, Necati Örmeci, Abdulalh Sonsuz, Mehmet Demir, Murat Kılıç, Ahmet Uygun, Ali Demir, Anıl Delik, Burcu Arslan, Figen Doran, Engin Altıntaş, Tuncer Temel, Ahmet Bektaş
The hepatocellular carcinoma (HCC) tumor marker alpha-fetoprotein (AFP) is only elevated in about half of the HCC patients, limiting its usefulness in following the effects of therapy or screening. New markers are needed. It has been previously noted that the inflammation markers C-reactive protein (CRP) and platelet-lymphocyte ratio (PLR) are prognostically important and may reflect HCC aggressiveness. We therefore examined these 2 markers in a low-AFP HCC cohort and found that for HCCs > 2 cm, both markers significantly rise with an increasing maximum tumor diameter (MTD)...
2019: Oncology
Janko Ahlbrandt, Martin Lablans, Katrin Glocker, Sophia Stahl-Toyota, Klaus Maier-Hein, Lena Maier-Hein, Frank Ückert
Information technology (IT) can enhance or change many scenarios in cancer research for the better. In this paper, we introduce several examples, starting with clinical data reuse and collaboration including data sharing in research networks. Key challenges are semantic interoperability and data access (including data privacy). We deal with gathering and analyzing genomic information, where cloud computing, uncertainties and reproducibility challenge researchers. Also, new sources for additional phenotypical data are shown in patient-reported outcome and machine learning in imaging...
November 15, 2018: Oncology
Shinichi Togami, Toshihiko Kawamura, Mika Fukuda, Shintaro Yanazume, Masaki Kamio, Hiroaki Kobayashi
OBJECTIVE: The detection accuracy of sentinel lymph node (SLN) metastasis by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) for endometrial cancer (EC) remains unclear and was assessed in this preliminary study. METHODS: We studied primary cancer tissues and pelvic lymph nodes (PLN) from 105 patients with EC. qRT-PCR assay was performed to determine the copy numbers of CK19 mRNA in EC tissues, and negative and positive LN samples. Further, qRT-PCR results were compared with pathological findings...
November 14, 2018: Oncology
Sanna Iivanainen, Jussi P Koivunen
BACKGROUND: Most clinical trials have investigated PD-(L)1 agents until disease progression or severe side effects, but the optimal duration of the treatment remains to be elucidated. Our institutional guideline has restricted maximal PD-(L)1 therapy length to 6 months, and therefore our cohort provides a unique opportunity to investigate the effects of short PD-1 therapy. METHODS: We retrospectively collected all patients who had been treated with PD-1 therapy for metastatic cancer at Oulu University Hospital from 2014 to 2018...
October 31, 2018: Oncology
Luke T Juckett, Doug I Lin, Russell Madison, Jeffrey S Ross, Alexa B Schrock, Siraj Ali
BACKGROUND: The Polycomb Repressive Complex 1 (PRC1) regulates epigenetic silencing and is manifestly linked to rare cancer types. The X-linked BCOR gene (BCL-6 Corepressor) is a member of the PRC1 complex and potentiates transcriptional repression through BCL6 binding of PRC1. Accumulating evidence suggests that internal tandem duplications (ITD) of BCOR are oncogenic drivers in a subset of pediatric sarcomas and rare adult tumors. OBJECTIVE: We reviewed the genomic profiles of a large series of advanced cancer patients to determine the frequency and genomic spectrum of ITD of BCOR across cancer...
October 31, 2018: Oncology
Dai Inoue, Shuhei Sekiguchi, Wataru Yamagata, Gen Maeda, Daiki Yamada, Shun Fujiwara, Shiori Itou, Masamichi Kurihara, Yuko Hijioka, Kohei Shimoji, Junko Fujiki, Ayano Nakazono, Hideyuki Horike, Atsushi Yoshioka, Yuki Ogura, Fumihiko Hatao, Kazuhiro Imamura, Shin Namiki
OBJECTIVES: The neutrophil-to-lymphocyte ratio (NLR) has been proposed as an indicator of cancer-related inflammation. The aim of our study was to examine the prognostic value of the NLR for patients with advanced gastric cancer receiving second-line chemotherapy. METHODS: The association of overall survival (OS) in second-line chemotherapy and the clinicopathological findings including NLR were analyzed retrospectively. The selection criteria were patients who received second-line chemotherapy between January 2010 and June 2015, had histologically confirmed gastric adenocarcinoma, and were followed up until death or for 180 days or longer...
October 26, 2018: Oncology
Paula Carrio-Cordo, Michael Baudis
Cancers arise from the accumulation of somatic genome mutations, with varying contributions of intrinsic (i.e., genetic predisposition) and extrinsic (i.e., environmental) factors. For the understanding of malignant clones, precise information about their genomic composition has to be correlated with morphological, clinical, and individual features in the context of the available medical knowledge. Rapid improvements in molecular profiling techniques, the accumulation of a large amount of data in genomic alterations in human malignancies, and the expansion of bioinformatic tools and methodologies have facilitated the understanding of the molecular changes during oncogenesis, and their correlation with clinicopathological phenotypes...
October 26, 2018: Oncology
Kaori Hayashi, Seiichiro Mitani, Hiroya Taniguchi, Hirofumi Yasui, Kei Muro, Keita Mori, Takuji Gotoda, Kentaro Yamazaki
OBJECTIVE: Anti-epithelial growth factor receptor (EGFR) antibodies cetuximab (Cmab) and panitumumab (Pmab) have shown survival benefit for metastatic colorectal cancer (mCRC) patients. This study aimed to compare Pmab and Cmab according to the interval between bevacizumab discontinuation and anti-EGFR antibody initiation (bevacizumab-free interval; BFI). METHODS: We retrospectively evaluated mCRC patients who received Cmab or Pmab in combination with irinotecan at two institutions...
October 25, 2018: Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"